Sign in
Not yet recruitingNo phase

Stapokibart given ahead of nose surgery for chronic sinus swelling with polyps

Tests stapokibart before nose surgery in adults with nasal polyps.

Key facts

Who runs it
Beijing Tongren Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps
Status
Not yet recruiting
People taking part
48 people, planned
Started
1 Jun 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Stapokibart
  • Matched placebo
Record updated
1 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe chronic rhinosinusitis with nasal polyps (long-lasting sinus swelling with growths in both sides of the nose) who have never had nose surgery. Participants get stapokibart or placebo for 4 weeks before endoscopic sinus surgery.

Age
18 to 75 years
Sex
All sexes
Disease stage
Nasal polyps on both sides. Nasal congestion plus loss of smell or runny nose for ≥12 weeks. Total NPS ≥ 4 points and ≥ 2 points in each side. Moderate to severe congestion or smell loss (score 2 or 3). Sinus CT Lund-Mackay score ≥12 points on both sides and ≥6 points on one side. Asthma, if present, must be stable.
Earlier treatment
No previous nose or sinus surgery. No previous anti-IL-4Rα biologic. People with asthma on a stable inhaled corticosteroid dose for at least 4 weeks can keep it, up to ≤1000 μg fluticasone propionate or equivalent per day.
Biomarker or test result
Signs of type 2 inflammation, one of: eosinophil count >55/high-power field or eosinophil percentage >27% in polyp tissue; blood eosinophil percentage ≥3.75% with asthma; or ≥6.9% without asthma.

Main reasons for not taking part

  • Previous nose or sinus surgery, or cannot have general anesthesia
  • Previous use of an anti-IL-4Rα biologic
  • Recent nose or airway infection, asthma attack within 4 weeks, allergic fungal sinusitis or nasal tumors
  • Poorly controlled serious diseases such as HIV, hepatitis B or C, tuberculosis, cancer, or weak immune system
  • Pregnancy, breastfeeding or planning pregnancy

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Possess the ability to understand the nature of the study and voluntarily sign an informed consent form (ICF)
  • Age between 18 and 75 years old, with no limitation on gender
  • Bilateral CRSwNP meeting the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2024)
  • Persistent presence of the following symptoms for ≥12 weeks prior to the screening/introduction period:
  • Nasal congestion
  • Any other symptom such as decreased/loss of smell or rhinorrhea
  • At the screening/introduction period and baseline, total NPS ≥ 4 points and NPS ≥ 2 points in each nasal cavity
  • At the screening/introduction period and baseline, the subject reports moderate to severe nasal congestion or decreased smell (NCS or LoS score of 2 or 3 points)
  • During the screening/introduction period, the Lund-Mackay score on sinus CT is ≥12 points bilaterally and ≥6 points unilaterally
  • Must meet any of the following criteria for type 2 inflammation: Eosinophil count >55/high-power field or eosinophil percentage >27% in nasal polyp tissue during the induction period; eosinophil percentage ≥3.75% in peripheral blood in patients with asthma; eosinophil percentage ≥6.9% in patients without asthma
  • If the subject has asthma, the condition must be stable as assessed by the investigator or specialist. For subjects treated with a stable dose of inhaled corticosteroids for at least 4 weeks before screening, the treatment may be continued during the study period, and the daily dose of inhaled corticosteroids must be ≤1000 μg fluticasone propionate or an equivalent dose of other inhaled corticosteroids

Who cannot take part

  • Previous ESS surgery including but not limited to septoplasty, turbinate reduction, nasal polyp removal, and sinus surgery
  • Contraindications to stapokibart therapy
  • Previous use of any anti-IL-4Rα biologic
  • The patient has conditions or comorbidities that may prevent them from being evaluated for the primary efficacy endpoint, such as acute rhinitis, nasal infection or upper respiratory tract infection within 2 weeks prior to the screening period, acute asthma exacerbation within 4 weeks, current drug-induced rhinitis, allergic fungal sinusitis (AFRS), benign or malignant nasal tumors
  • Important clinical comorbidities that may interfere with clinical efficacy results, including but not limited to active upper or lower respiratory tract infection, cystic fibrosis, eosinophilic granuloma with polyangiitis (Churg-Strauss syndrome), granuloma with polyangiitis (Wegener's granulomatosis), Young's syndrome, etc
  • Accompanied by other poorly controlled serious diseases or recurrent chronic diseases such as (but not limited to) active infection, cardiovascular disease, tuberculosis or other pathogen infection, diabetes, autoimmune diseases, HIV, hepatitis B, hepatitis C or parasitic diseases, malignant tumors, etc
  • Subjects with known or suspected immunosuppression, including those with a history of invasive opportunistic infections (such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cystitis, aspergillosis), even if the infection has subsided
  • Subjects with a history of alcohol or drug abuse
  • Subjects deemed by the investigator to have other medical or non-medical conditions that make them unsuitable for participation in this study
  • Subjects with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels > 2 times the upper limit of normal, and serum creatinine > the upper limit of normal
  • Subjects of childbearing age who do not wish to use medically approved effective contraception
  • Contraindications to general anesthesia
  • Women who are pregnant or planning to become pregnant during the study period, or who are breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-center, randomized, double-blinded, placebo-controlled clinical trial in adults with moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have no previous nasal surgery.

Read full original descriptionShow less

The purpose of this study is to evaluate the effectiveness and safety of using stapokibart for 4 weeks before endoscopic sinus surgery (ESS), compared with placebo before ESS.

The main questions this study aims to answer are:

* Does preoperative stapokibart combined with endoscopic sinus surgery achieve better efficacy and comparable safety compared with surgery alone? * What influences four-week preoperative stapokibart administration has on pharmacodynamic data and intraoperative surgical parameters? * Is there a correlation between the efficacy of four-week stapokibart therapy and postoperative recurrence tendency after endoscopic sinus surgery?

Researchers will randomly assign participants to receive either stapokibart or a placebo (an inactive substance that looks like the study drug) for 4 weeks before surgery. All participants will have the same standard endoscopic sinus surgery and will be followed for 48 weeks to check polyp status, symptoms, quality of life, and adverse events.

This study will provide evidence about whether short-term preoperative stapokibart improves surgical and long-term outcomes for adults with CRSwNP undergoing ESS.

The 2 groups in the trial

  • Stapokibart Treatment GroupTreatment being tested

    Eligible CRSwNP participants receive 300 mg stapokibart by subcutaneous injection every other week. Two weeks after the second injection, they undergo bilateral full-group sinus opening under general anesthesia via endoscopic sinus surgery. Postoperative follow-up lasted until 48 weeks. Throughout the entire study period, all participants receive routine maintenance treatment with nasal corticosteroid spray.

    Treatment: Stapokibart

  • Placebo Control GroupPlacebo, for comparison

    Eligible CRSwNP participants receive matched placebo by subcutaneous injection every other week. Two weeks after the second injection, they undergo bilateral full-group sinus opening under general anesthesia via endoscopic sinus surgery. Postoperative follow-up lasts until 48 weeks. Throughout the entire study period, all participants receive routine maintenance treatment with nasal corticosteroid spray.

    Treatment: Matched placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-Controlled, Double-Blinded Trial of Preoperative Stapokibart With Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps
Plain-language title
Stapokibart given ahead of nose surgery for chronic sinus swelling with polypsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT07616609, who can take part
Record updated
1 June 2026